BACKGROUND: The ability to detect neoplasia-specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal treatment is chosen. However, the available methodologies to detect such fusions all have their distinct short-comings. RESULTS: We describe a novel oligonucleotide microarray strategy whereby one can screen for all known oncogenic fusion transcripts in a single experiment. To accomplish this, we combine measurements of chimeric transcript junctions with exon-wise measurements of individual fusion partners. To demonstrate the usefulness of the approach, we designed a DNA microarray containing 68,861 oligonucleotide probes that includes oligos covering all combinations of chimeric exon-exon junctions from 275 pairs of fusion genes, as well as sets of oligos internal to all the exons of the fusion partners. Using this array, proof of principle was demonstrated by detection of known fusion genes (such as TCF3:PBX1, ETV6:RUNX1, and TMPRSS2:ERG) from all six positive controls consisting of leukemia cell lines and prostate cancer biopsies. CONCLUSION: This new method bears promise of an important complement to currently used diagnostic and research tools for the detection of fusion genes in neoplastic diseases.
BACKGROUND: The ability to detect neoplasia-specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal treatment is chosen. However, the available methodologies to detect such fusions all have their distinct short-comings. RESULTS: We describe a novel oligonucleotide microarray strategy whereby one can screen for all known oncogenic fusion transcripts in a single experiment. To accomplish this, we combine measurements of chimeric transcript junctions with exon-wise measurements of individual fusion partners. To demonstrate the usefulness of the approach, we designed a DNA microarray containing 68,861 oligonucleotide probes that includes oligos covering all combinations of chimeric exon-exon junctions from 275 pairs of fusion genes, as well as sets of oligos internal to all the exons of the fusion partners. Using this array, proof of principle was demonstrated by detection of known fusion genes (such as TCF3:PBX1, ETV6:RUNX1, and TMPRSS2:ERG) from all six positive controls consisting of leukemia cell lines and prostate cancer biopsies. CONCLUSION: This new method bears promise of an important complement to currently used diagnostic and research tools for the detection of fusion genes in neoplastic diseases.
Authors: A Brazma; P Hingamp; J Quackenbush; G Sherlock; P Spellman; C Stoeckert; J Aach; W Ansorge; C A Ball; H C Causton; T Gaasterland; P Glenisson; F C Holstege; I F Kim; V Markowitz; J C Matese; H Parkinson; A Robinson; U Sarkans; S Schulze-Kremer; J Stewart; R Taylor; J Vilo; M Vingron Journal: Nat Genet Date: 2001-12 Impact factor: 38.330
Authors: Nuno Cerveira; Franclim R Ribeiro; Ana Peixoto; Vera Costa; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira Journal: Neoplasia Date: 2006-10 Impact factor: 5.715
Authors: Yijun Ruan; Hong Sain Ooi; Siew Woh Choo; Kuo Ping Chiu; Xiao Dong Zhao; K G Srinivasan; Fei Yao; Chiou Yu Choo; Jun Liu; Pramila Ariyaratne; Wilson G W Bin; Vladimir A Kuznetsov; Atif Shahab; Wing-Kin Sung; Guillaume Bourque; Nallasivam Palanisamy; Chia-Lin Wei Journal: Genome Res Date: 2007-06 Impact factor: 9.043
Authors: Beth E Helgeson; Scott A Tomlins; Nameeta Shah; Bharathi Laxman; Qi Cao; John R Prensner; Xuhong Cao; Nirmish Singla; James E Montie; Sooryanarayana Varambally; Rohit Mehra; Arul M Chinnaiyan Journal: Cancer Res Date: 2008-01-01 Impact factor: 12.701
Authors: Peter J Campbell; Philip J Stephens; Erin D Pleasance; Sarah O'Meara; Heng Li; Thomas Santarius; Lucy A Stebbings; Catherine Leroy; Sarah Edkins; Claire Hardy; Jon W Teague; Andrew Menzies; Ian Goodhead; Daniel J Turner; Christopher M Clee; Michael A Quail; Antony Cox; Clive Brown; Richard Durbin; Matthew E Hurles; Paul A W Edwards; Graham R Bignell; Michael R Stratton; P Andrew Futreal Journal: Nat Genet Date: 2008-04-27 Impact factor: 38.330
Authors: Sameer Jhavar; Alison Reid; Jeremy Clark; Zsofia Kote-Jarai; Timothy Christmas; Alan Thompson; Christopher Woodhouse; Christopher Ogden; Cyril Fisher; Cathy Corbishley; Johann De-Bono; Rosalind Eeles; Daniel Brewer; Colin Cooper Journal: J Mol Diagn Date: 2007-12-28 Impact factor: 5.568
Authors: Markku Miettinen; Anna Felisiak-Golabek; Alejandro Luiña Contreras; John Glod; Rosandra N Kaplan; Jonathan Keith Killian; Jerzy Lasota Journal: Hum Pathol Date: 2019-01-08 Impact factor: 3.466
Authors: Roberto Plebani; Gavin R Oliver; Marco Trerotola; Emanuela Guerra; Pamela Cantanelli; Luana Apicella; Andrew Emerson; Alessandro Albiero; Paul D Harkin; Richard D Kennedy; Saverio Alberti Journal: Neoplasia Date: 2012-11 Impact factor: 5.715
Authors: Wen Luo; Brett Milash; Brian Dalley; Richard Smith; Holly Zhou; Natalie Dutrow; Bradley R Cairns; Stephen L Lessnick Journal: EMBO Mol Med Date: 2012-03-15 Impact factor: 12.137
Authors: Gard O S Thomassen; Alexander D Rowe; Karin Lagesen; Jessica M Lindvall; Torbjørn Rognes Journal: PLoS One Date: 2009-06-17 Impact factor: 3.240
Authors: Marthe Løvf; Gard O S Thomassen; Fredrik Mertens; Nuno Cerveira; Manuel R Teixeira; Ragnhild A Lothe; Rolf I Skotheim Journal: PLoS One Date: 2013-08-13 Impact factor: 3.240